Neogenomics earnings release, July 28, 2026

Neogenomics Inc (NEO) · Form 8-K, Item 2.02 · Filed · SEC filing

NeoGenomics Reports Second Quarter 2026 Results

Total revenue increased 11% YoY to $202 million

Clinical services revenue grew 14%, with NGS revenue growth of 26%

Company raises full-year 2026 revenue and adjusted EBITDA guidance

Fort Myers, Florida (July 28, 2026) - NeoGenomics, Inc. (NASDAQ: NEO) (the

“

Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2026.

“Our second quarter results reflect the consistent operating and financial performance investors expect from this team,” said Tony Zook, Chief Executive Officer of NeoGenomics. “Revenue growth of 11% year-over-year exceeded our outlook, with NGS revenue growth of 26% reflecting a continued mix shift to more advanced testing modalities. This revenue growth is being coupled with our focus on disciplined margin expansion, as evidenced by adjusted EBITDA increasing by 36%. Looking ahead, I remain confident that we are well positioned to deliver long-term profitable growth, while investing in our business and expanding our suite of on-market testing solutions for patients and providers.”

Second-Quarter Results

Consolidated revenue for the second quarter of 2026 was $202 million, an increase of 11% over the same period in 2025. Clinical volume increased by 2%, while average revenue per clinical test increased by 12% to $515.

Consolidated gross profit for the second quarter of 2026 was $92 million, an increase of 19% compared to the second quarter of 2025. Consolidated gross profit margin, including amortization of acquired intangible assets and stock-based

NeoGenomics, Inc. | 9490 NeoGenomics Way Fort Myers, FL 33912

Page

2 compensation expense, was 46%. Adjusted Gross Profit Margin

(1), excluding amortization of acquired intangible assets and stock-based compensation expense, was 48%, an increase of 260 bps versus the same period in 2025.

Operating expenses for the second quarter of 2026 were $102 million, a decrease of $23 million, or 19%, compared to the second quarter of 2025. The decrease in operating expenses was primarily due to $20 million of impairment charges taken in the second quarter of 2025.

Net income for the quarter was $2 million compared to net loss of $45 million for the second quarter of 2025. Net income for the quarter includes a gain on extinguishment of debt of $11 million.

Adjusted EBITDA

Financial statements

Income Statement

Previous FY 2026 Guidance — The Company is revising its full-year 2026 guidance, as shown below (in millions).

FY 2025 – ActualPrevious FY 2026 Guidance – LowPrevious FY 2026 Guidance – HighUpdated FY 2026 Guidance – LowUpdated FY 2026 Guidance – HighYOY % Change from FY 2025 – LowYOY % Change from FY 2025 – High
Consolidated revenue72779780380280610.0%11.0%
Net loss-108-63-50-42-3461.0%69.0%
Adjusted EBITDA435557565829.0%34.0%

Income Statement

Three Months Ended June 30, — (unaudited)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
NET REVENUE201,656181,330388,328349,365
COST OF REVENUE109,778104,072215,586198,861
GROSS PROFIT91,87877,258172,742150,504
Operating expenses:General and administrative63,61371,747129,354139,954
Operating expenses:Research and development10,7619,02320,29519,204
Operating expenses:Sales and marketing27,27524,07551,10546,758
Operating expenses:Impairment charges20,04120,041
Operating expenses:Total operating expenses101,649124,886200,754225,957
Operating expenses:LOSS FROM OPERATIONS-9,771-47,628-28,012-75,453
Operating expenses:Interest income1,2142,2632,4875,984
Operating expenses:Interest expense-781-933-1,379-2,551
Operating expenses:Other (expense) income, net-17482-29547
Operating expenses:Gain on extinguishment of debt11,18111,181
Operating expenses:Income (loss) before taxes1,826-45,816-15,752-71,473
Operating expenses:Income tax benefit412724884458
Operating expenses:NET INCOME (LOSS)2,238-45,092-14,868-71,015
NET INCOME (LOSS) PER SHAREBasic0.02-0.35-0.11-0.56
NET INCOME (LOSS) PER SHAREDiluted0.02-0.35-0.11-0.56
WEIGHTED AVERAGE COMMON SHARES OUTSTANDINGBasic129,628127,949129,398127,664
WEIGHTED AVERAGE COMMON SHARES OUTSTANDINGDiluted130,831127,949129,398127,664

Income Statement

Three Months Ended June 30, — (unaudited)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net income (loss) (GAAP)2,238-45,092-14,868-71,015
Adjustments to net income (loss):Interest income-1,214-2,263-2,487-5,984
Adjustments to net income (loss):Interest expense7819331,3792,551
Adjustments to net income (loss):Income tax benefit-412-724-884-458
Adjustments to net income (loss):Depreciation8,5779,14017,35718,506
Adjustments to net income (loss):Amortization7,9748,12415,60716,486
Adjustments to net income (loss):EBITDA (non-GAAP)17,944-29,88216,104-39,914
Further adjustments to EBITDA:Leadership transition costs(1)2456375632,831
Further adjustments to EBITDA:Acquisition and integration related expenses(2)3,2048064,376
Further adjustments to EBITDA:Stock-based compensation expense8,21612,21517,85222,968
Further adjustments to EBITDA:Gain on extinguishment of debt-11,181-11,181
Further adjustments to EBITDA:Impairment charges(3)20,04120,041
Further adjustments to EBITDA:IP litigation costs(4)814,4601657,443
Further adjustments to EBITDA:Adjustment to contingency for regulatory matter-1,155-1,155
Further adjustments to EBITDA:Other significant expenses, net(5)317317
Further adjustments to EBITDA:Adjusted EBITDA (non-GAAP)14,46710,67523,47117,745

Income Statement

Three Months Ended June 30, — (unaudited)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Three Months Ended June 30, – 2025Three Months Ended June 30, – % ChangeSix Months Ended June 30, – 2026Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025Six Months Ended June 30, – 2025Six Months Ended June 30, – % Change
Consolidated:Total revenue (GAAP)201,656181,33011.2%388,328349,36511.2%
Consolidated:Cost of revenue (GAAP)109,778104,0725.5%215,586198,8618.4%
Consolidated:Adjustments to cost of revenue(1)-5,021-5,114-9,972-10,439
Consolidated:Adjusted cost of revenue (non-GAAP)104,75798,9585.9%205,614188,4229.1%
Consolidated:Gross profit (GAAP)91,87877,25818.9%172,742150,50414.8%
Consolidated:Adjusted gross profit (non-GAAP )96,89982,37217.6%182,714160,94313.5%
Consolidated:Gross profit margin (GAAP)45.6%42.6%44.5%43.1%
Consolidated:Adjusted gross profit margin (non-GAAP)48.1%45.4%47.1%46.1%

Income Statement

Three Months Ended June 30, — (unaudited)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net income (loss) (GAAP)2,238-45,092-14,868-71,015
Adjustments to net income (loss) net of tax:Amortization7,9748,12415,60716,486
Adjustments to net income (loss) net of tax:Leadership transition costs(1)2456375632,831
Adjustments to net income (loss) net of tax:Acquisition and integration related expenses(2)3,2048064,376
Adjustments to net income (loss) net of tax:Stock-based compensation expense8,21612,21517,85222,968
Adjustments to net income (loss) net of tax:Gain on extinguishment of debt-11,181-11,181

Income Statement

Year Ended December 31, 2026

Year Ended December 31, 2026 – Low RangeYear Ended December 31, 2026 – High Range
Net loss (GAAP)-42,000-34,000
Amortization32,00032,000
Stock-based compensation expenses37,00035,000
Other one-time expenses-5,000-7,000
Adjusted net income (non-GAAP)22,00026,000
Interest and taxes-2,000-2,000
Depreciation36,00034,000
Adjusted EBITDA (non-GAAP)56,00058,000
Net loss per diluted share (GAAP)-0.32-0.26
Adjustments to net loss per diluted share:Amortization0.250.25
Adjustments to net loss per diluted share:Stock-based compensation expenses0.280.27
Adjustments to net loss per diluted share:Other one-time expenses-0.04-0.05
Adjustments to net loss per diluted share:Rounding and impact of diluted shares in adjusted diluted shares(1)-0.01
Adjustments to net loss per diluted share:Adjusted diluted EPS (non-GAAP)0.170.2
Weighted average assumed shares outstanding in 2026:Diluted shares (GAAP)130,000130,000
Weighted average assumed shares outstanding in 2026:Adjusted diluted shares outstanding (non-GAAP)130,000130,000

Balance Sheet

December 31, 2025 — (in thousands)

June 30, 2026 (unaudited)December 31, 2025
Current assetsCash and cash equivalents145,539159,618
Current assetsAccounts receivable, net175,405159,242
Current assetsInventories27,13728,566
Current assetsPrepaid assets23,59021,443
Current assetsOther current assets9,8077,417
Current assetsTotal current assets381,478376,286
Current assetsProperty and equipment, net80,93884,834
Current assetsOperating lease right-of-use assets78,60678,444
Current assetsFinancing lease right-of-use assets6,65354
Current assetsIntangible assets, net271,262286,528
Current assetsGoodwill523,995524,344
Current assetsOther assets9,3119,340
Current assetsTotal non-current assets970,765983,544
Current assetsTotal assets1,352,2431,359,830
Current liabilitiesAccounts payable and other current liabilities100,45783,496
Current liabilitiesCurrent portion of operating lease liabilities3,7224,776
Current liabilitiesCurrent portion of finance lease liabilities1,70428
Current liabilitiesTotal current liabilities105,88388,300
Long-term liabilitiesOperating lease liabilities64,67162,822
Long-term liabilitiesFinance lease liabilities4,03027
Long-term liabilitiesConvertible senior notes, net374,241341,858
Long-term liabilitiesDeferred income tax liabilities, net16,82418,219
Long-term liabilitiesOther long-term liabilities86212,042
Long-term liabilitiesTotal long-term liabilities460,628434,968
Long-term liabilitiesTotal liabilities566,511523,268
Stockholders’ equityTotal stockholders' equity785,732836,562
Stockholders’ equityTotal liabilities and stockholders’ equity1,352,2431,359,830

Cash Flow

Six Months Ended June 30, — (unaudited)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
CASH FLOWS FROM OPERATING ACTIVITIESNet loss-14,868-71,015
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Depreciation17,35618,506
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Amortization of intangibles15,26716,486
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Stock-based compensation17,85222,968
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:Non-cash operating lease expense3,2263,346
Full release

(1) for the second quarter of 2026 increased by 36% to $14 million, compared to $11 million in the second quarter of 2025. Adjusted Net Income

(1) was $7 million compared to Adjusted Net Income

(1) of $4 million in the second quarter of 2025.

Cash and cash equivalents totaled $146 million at quarter end. This reflects the net effects from the completion of the company’s $316 million private offering of 0.75% convertible senior notes due 2032. As part of the transaction, the Company repurchased approximately $276 million aggregate principal amount of the Company’s existing 0.25% convertible senior notes due 2028 and entry into capped call transactions intended to reduce potential dilution upon conversion. Company also repurchased shares of its common stock for an aggregate purchase price of $25 million.

(1)

The Company has provided adjusted financial information that has not been prepared in accordance with GAAP, including Adjusted EBITDA, Adjusted Gross Profit Margin, Adjusted Net (Loss) Income, and Adjusted Diluted EPS. Each of these measures is defined in the section of this press release entitled “Use of Non-GAAP Financial Measures.” See also the tables reconciling such measures to their closest GAAP equivalent.

2026 Financial Guidance

The Company is revising its full-year 2026 guidance, as shown below (in millions).

Conference Call

The Company has scheduled a webcast and conference call to discuss its second quarter 2026 results on Tuesday,

July 28, 2026 at 4:30 p.m. Eastern Time. To access the live call via telephone, interested investors should dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 968605. The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Company’s website.

About NeoGenomics, Inc.

NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.

We routinely post information that may be important to investors on our website at https://www.neogenomics.com. Information on, or accessible through, our website is not incorporated by reference into, and is not a part of, this release or any other report or document that we may file with the Securities and Exchange Commission (“SEC”).

NeoGenomics, Inc. | 9490 NeoGenomics Way Fort Myers, FL 33912

Page

2

Forward Looking Statements... (truncated) forward-looking statements include statements regarding the Company’s strategy, planned future operations and related expectations with respect to timing and performance, capital structure and future financial position, future operating and financial performance, growth potential and expected growth drivers, projected costs and capital expenditures, prospects and plans, and estimates of market size and position, as well as statements regarding the objectives of management. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to execute on its strategic priorities, to enter new markets and increase market share in both current and new markets, to continue gaining new customers, develop and commercialize new types of tests, manage the effects of seasonality, execute on its long-range strategic priorities and otherwise implement its business plans, as well as the potential impact of evolving regulatory requirements related to laboratory developed tests, the impact of tariffs and trade policy uncertainty on the Company's supply chain and costs, and any potential reimbursement changes by the government and commercial payors, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 and filed with the SEC on February 17, 2026, as well as subsequently filed Quarterly Reports on Form 10-Q and the Company's other filings with the SEC.

We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Investor Contact

InvestorRelations@neogenomics.com

Media Contact

Andrea Sampson asampson@sampsonprgroup.com

NeoGenomics, Inc. | 9490 NeoGenomics Way Fort Myers, FL 33912

Page

3

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Neogenomics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.